

**Research Compliance Activity and Turn-Around-Time (TAT) Summary Report**  
**Fiscal Year 2021 (7/1/2020 to 6/30/2021)**

*TAT calculated from submission date to date of approval. TAT not calculated for continuing reviews.*

<b>Institutional Biosafety Committee (IBC) - IUPUI</b>								
	<b>Q1 TAT</b>		<b>Q2 TAT</b>		<b>Q3 TAT</b>		<b>Q4 TAT</b>	
	<b>Mean</b>	<b>Median</b>	<b>Mean</b>	<b>Median</b>	<b>Mean</b>	<b>Median</b>	<b>Mean</b>	<b>Median</b>
<b>Full Board</b>								
New Studies - Full Board (to review)	29.1	28.0	26.5	22.0	27.9	31.0	27.0	24.0
New Studies - Full Board (to approval)	38.6	42.0	49.5	46.0	33.8	31.5	44.3	44.0
<b>Exempt</b>								
New Studies - Exempt (to determination)	18.08	14.0	28.6	20.5	29.8	19.5	21.0	16.0
<b>Amendments</b>								
Amendments - Minor	4.5	1.5	5.8	1.0	5.8	3.0	3.7	1.0
Amendments - Major	29.0	20.0	25.2	20.0	19.8	12.0	20.8	13.0

<b>Area Activities/Throughput (T)</b>	<b>Q1 (Jul-Sep)</b>			<b>Q2 (Oct-Dec)</b>			<b>Q3 (Jan-Mar)</b>			<b>Q4 (Apr-Jun)</b>		
	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged	Received	Completed	Throughput/ % Backlogged
New Studies - Full Board	19	21	2	8	13	5	18	17	-1 (5.6%)	17	18	1
New Studies - Exempt	14	10	-4 (28.6%)	12	9	-3 (25.0%)	13	16	3	5	7	2
Amendments - Minor	121	116	-5 (4.1%)	120	113	-7 (5.8%)	132	157	25	153	153	0
Amendments - Major	26	32	6	19	22	3	20	24	4	26	20	-6 (23.1%)
Continuing Reviews	81	83	2	94	93	-1 (1.1%)	102	106	4	77	82	5
<b>TOTAL</b>	<b>261</b>	<b>262</b>	<b>1 (-0.4%)</b>	<b>253</b>	<b>250</b>	<b>-3 (1.2%)</b>	<b>285</b>	<b>320</b>	<b>35 (-12.3%)</b>	<b>278</b>	<b>280</b>	<b>2 (-0.7%)</b>

<b>Area Training Activities</b>	<b>Q1 (Jul-Sep)</b>	<b>Q2 (Oct-Dec)</b>	<b>Q3 (Jan-Mar)</b>	<b>Q4 (Apr-Jun)</b>	<b>FY TOTALS</b>
Presentations (# of events)	0	1	1	1	3

<b>Reportable Events/Activities</b>	<b>Q1 (Jul-Sep)</b>	<b>Q2 (Oct-Dec)</b>	<b>Q3 (Jan-Mar)</b>	<b>Q4 (Apr-Jun)</b>	<b>FY TOTALS</b>
Immediate OBA Report	0	0	0	0	0
30 Day OBA Report	0	1	2	0	3
Lab Accident/Injury/Exposure	0	3	1	0	4

Reporting Agency: NIH Office of Biotechnology Activities (OBA)